Xilio Therapeutics (XLO) Asset Utilization Ratio (2025 - 2026)
Xilio Therapeutics (XLO) reported Asset Utilization Ratio of 0.34 for Q1 2026, up 216.82% on a YoY basis from 0.11 in Q1 2025, and up 10.76% sequentially from 0.3 in Q4 2025.
Xilio Therapeutics (XLO) Asset Utilization Ratio (2025 - 2026) Analysis & Trends
Xilio Therapeutics (XLO) has 2 years of Asset Utilization Ratio data on file, last reported at 0.34 in Q1 2026.
- For the quarter ending Q1 2026, Asset Utilization Ratio rose 216.82% year-over-year to 0.34; the trailing twelve-month figure through Mar 2026 stood at 0.34 (up 216.82% YoY), and the FY2025 full-year result was 0.39, up 303.37% from the prior year.
- Asset Utilization Ratio improved to 0.34 in Q1 2026, from 0.3 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.34 in Q1 2026 to a low of 0.11 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 0.69 |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 0.47 |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 0.37 |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Xilio Therapeutics | 148.60 Mn | -1.70 Mn | - | 0.34 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.34 |
| Dec 31, 2025 | 0.30 |
| Sep 30, 2025 | 0.24 |
| Jun 30, 2025 | 0.13 |
| Mar 31, 2025 | 0.11 |